SrasV1, PascalFrancis, Corpus, bibRecord, 000539

Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors

Identifieur interne : 000539 ( PascalFrancis/Corpus ); précédent : 000538; suivant : 000540

Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors

Auteurs : Arun K. Ghosh ; KAI XI ; Kiira Ratia ; Bernard D. Santarsiero ; WENTAO FU ; Brian H. Harcourt ; Paul A. Rota ; Susan C. Baker ; Michael E. Johnson ; Andrew D. Mesecar

Source :

Journal of medicinal chemistry : (Print) [ 0022-2623 ] ; 2005.

RBID : Pascal:06-0152064

Descripteurs français

Pascal (Inist)
- Synthèse chimique, Composé peptidomimétique, Virus syndrome respiratoire aigu sévère, Inhibiteur protease, Composé non peptide, Cétoamide, Carboxamide, Lactame, Hétérocycle oxygène azote, Hétérocycle azote, In vitro, Complexe enzyme inhibiteur, Modèle moléculaire, Activité biologique, Composé vinylique, Peptidases, Inhibiteur enzyme, Antiviral, Modélisation, Pyrrolidine-3-pent-2-énoïque acide(γ-[(5-méthyl-2-[4-méthyl-3-([(5-méthylisoxazol-3-yl)carbonyl]amino)-2-oxopentyl]hex-4-énoyl)amino]-2-oxo) ester éthyle, Pyrrolidin-2-one dérivé, Isoxazole-3-carboxamide dérivé.

English descriptors

KwdEn :
- Antiviral, Biological activity, Carboxamide, Chemical synthesis, Enzyme inhibitor, In vitro, Inhibitor enzyme complex, Ketoamide, Lactam, Modeling, Molecular model, Nitrogen heterocycle, Non peptide compound, Oxygen nitrogen heterocycle, Peptidases, Peptidomimetic compound, Protease inhibitor, Severe acute respiratory syndrome virus, Vinylic compound.

Abstract

Design, synthesis, and biological evaluation of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease (SARS-3CLpro) inhibitors for severe acute respiratory syndrome coronavirus (SARS-CoV) are described. These inhibitors exhibited antiviral activity against SARS-CoV in infected cells in the micromolar range. An X-ray crystal structure of our lead inhibitor (4) bound to SARS-3CLpro provided important drug-design templates for the design of small-molecule inhibitors.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0022-2623`
A02	`01`			`@0 JMCMAR`
A03		`1`		`@0 J. med. chem. : (Print)`
A05				`@2 48`
A06				`@2 22`
A08	`01`	`1`	`ENG`	`@1 Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors`
A11	`01`	`1`		`@1 GHOSH (Arun K.)`
A11	`02`	`1`		`@1 KAI XI`
A11	`03`	`1`		`@1 RATIA (Kiira)`
A11	`04`	`1`		`@1 SANTARSIERO (Bernard D.)`
A11	`05`	`1`		`@1 WENTAO FU`
A11	`06`	`1`		`@1 HARCOURT (Brian H.)`
A11	`07`	`1`		`@1 ROTA (Paul A.)`
A11	`08`	`1`		`@1 BAKER (Susan C.)`
A11	`09`	`1`		`@1 JOHNSON (Michael E.)`
A11	`10`	`1`		`@1 MESECAR (Andrew D.)`
A14	`01`			`@1 Departments of Chemistry and Medicinal Chemistry, Purdue University @2 West Lafayette, Indiana 47907 @3 USA @Z 1 aut. @Z 2 aut.`
A14	`02`			`@1 Center for Pharmaceutical Biotechnology and Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S @2 Ashland, Illinois 60607 @3 USA @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 9 aut. @Z 10 aut.`
A14	`03`			`@1 Center for Disease Control and Prevention @2 Atlanta, Georgia @3 USA @Z 6 aut.`
A14	`04`			`@1 Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine @2 Maywood, Illinois @3 USA @Z 7 aut. @Z 8 aut.`
A14	`05`			`@1 Department of Chemistry, University of Illinois at Chicago @2 Chicago, Illinois 60607 @3 USA`
A20				`@1 6767-6771`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 9165 @5 354000131970830010`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 18 ref.`
A47	`01`	`1`		`@0 06-0152064`
A60				`@1 P @3 CR`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of medicinal chemistry : (Print)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	`@0 Design, synthesis, and biological evaluation of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease (SARS-3CLpro) inhibitors for severe acute respiratory syndrome coronavirus (SARS-CoV) are described. These inhibitors exhibited antiviral activity against SARS-CoV in infected cells in the micromolar range. An X-ray crystal structure of our lead inhibitor (4) bound to SARS-3CLpro provided important drug-design templates for the design of small-molecule inhibitors.`
C02	`01`	`X`		`@0 002B02S05`
C03	`01`	`X`	`FRE`	`@0 Synthèse chimique @5 01`
C03	`01`	`X`	`ENG`	`@0 Chemical synthesis @5 01`
C03	`01`	`X`	`SPA`	`@0 Síntesis química @5 01`
C03	`02`	`X`	`FRE`	`@0 Composé peptidomimétique @5 02`
C03	`02`	`X`	`ENG`	`@0 Peptidomimetic compound @5 02`
C03	`02`	`X`	`SPA`	`@0 Compuesto peptidomimético @5 02`
C03	`03`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 03`
C03	`03`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 03`
C03	`03`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 03`
C03	`04`	`X`	`FRE`	`@0 Inhibiteur protease @2 FR @5 05`
C03	`04`	`X`	`ENG`	`@0 Protease inhibitor @2 FR @5 05`
C03	`04`	`X`	`SPA`	`@0 Inhibidor proteasa @2 FR @5 05`
C03	`05`	`X`	`FRE`	`@0 Composé non peptide @5 06`
C03	`05`	`X`	`ENG`	`@0 Non peptide compound @5 06`
C03	`05`	`X`	`SPA`	`@0 Compuesto no péptido @5 06`
C03	`06`	`X`	`FRE`	`@0 Cétoamide @5 08`
C03	`06`	`X`	`ENG`	`@0 Ketoamide @5 08`
C03	`06`	`X`	`SPA`	`@0 Cetoamida @5 08`
C03	`07`	`X`	`FRE`	`@0 Carboxamide @5 09`
C03	`07`	`X`	`ENG`	`@0 Carboxamide @5 09`
C03	`07`	`X`	`SPA`	`@0 Carboxamida @5 09`
C03	`08`	`X`	`FRE`	`@0 Lactame @5 10`
C03	`08`	`X`	`ENG`	`@0 Lactam @5 10`
C03	`08`	`X`	`SPA`	`@0 Lactamo @5 10`
C03	`09`	`X`	`FRE`	`@0 Hétérocycle oxygène azote @5 11`
C03	`09`	`X`	`ENG`	`@0 Oxygen nitrogen heterocycle @5 11`
C03	`09`	`X`	`SPA`	`@0 Heterociclo oxígeno nitrógeno @5 11`
C03	`10`	`X`	`FRE`	`@0 Hétérocycle azote @5 12`
C03	`10`	`X`	`ENG`	`@0 Nitrogen heterocycle @5 12`
C03	`10`	`X`	`SPA`	`@0 Heterociclo nitrógeno @5 12`
C03	`11`	`X`	`FRE`	`@0 In vitro @5 13`
C03	`11`	`X`	`ENG`	`@0 In vitro @5 13`
C03	`11`	`X`	`SPA`	`@0 In vitro @5 13`
C03	`12`	`X`	`FRE`	`@0 Complexe enzyme inhibiteur @5 14`
C03	`12`	`X`	`ENG`	`@0 Inhibitor enzyme complex @5 14`
C03	`12`	`X`	`SPA`	`@0 Complejo enzima inhibidor @5 14`
C03	`13`	`X`	`FRE`	`@0 Modèle moléculaire @5 15`
C03	`13`	`X`	`ENG`	`@0 Molecular model @5 15`
C03	`13`	`X`	`SPA`	`@0 Modelo molecular @5 15`
C03	`14`	`X`	`FRE`	`@0 Activité biologique @5 16`
C03	`14`	`X`	`ENG`	`@0 Biological activity @5 16`
C03	`14`	`X`	`SPA`	`@0 Actividad biológica @5 16`
C03	`15`	`X`	`FRE`	`@0 Composé vinylique @5 17`
C03	`15`	`X`	`ENG`	`@0 Vinylic compound @5 17`
C03	`15`	`X`	`SPA`	`@0 Compuesto vinílico @5 17`
C03	`16`	`X`	`FRE`	`@0 Peptidases @2 FE @5 32`
C03	`16`	`X`	`ENG`	`@0 Peptidases @2 FE @5 32`
C03	`16`	`X`	`SPA`	`@0 Peptidases @2 FE @5 32`
C03	`17`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 33`
C03	`17`	`X`	`ENG`	`@0 Enzyme inhibitor @5 33`
C03	`17`	`X`	`SPA`	`@0 Inhibidor enzima @5 33`
C03	`18`	`X`	`FRE`	`@0 Antiviral @5 34`
C03	`18`	`X`	`ENG`	`@0 Antiviral @5 34`
C03	`18`	`X`	`SPA`	`@0 Antiviral @5 34`
C03	`19`	`X`	`FRE`	`@0 Modélisation @5 35`
C03	`19`	`X`	`ENG`	`@0 Modeling @5 35`
C03	`19`	`X`	`SPA`	`@0 Modelización @5 35`
C03	`20`	`X`	`FRE`	`@0 Pyrrolidine-3-pent-2-énoïque acide(γ-[(5-méthyl-2-[4-méthyl-3-([(5-méthylisoxazol-3-yl)carbonyl]amino)-2-oxopentyl]hex-4-énoyl)amino]-2-oxo) ester éthyle @2 NK @2 FR @4 INC @5 76`
C03	`21`	`X`	`FRE`	`@0 Pyrrolidin-2-one dérivé @2 NK @4 INC @5 77`
C03	`22`	`X`	`FRE`	`@0 Isoxazole-3-carboxamide dérivé @2 NK @4 INC @5 78`
C07	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`05`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`05`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`06`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`06`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`06`	`X`	`SPA`	`@0 Enzima @2 FE`
N21				`@1 093`

Format Inist (serveur)

NO :	PASCAL 06-0152064 INIST
ET :	Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors
AU :	GHOSH (Arun K.); KAI XI; RATIA (Kiira); SANTARSIERO (Bernard D.); WENTAO FU; HARCOURT (Brian H.); ROTA (Paul A.); BAKER (Susan C.); JOHNSON (Michael E.); MESECAR (Andrew D.)
AF :	Departments of Chemistry and Medicinal Chemistry, Purdue University/West Lafayette, Indiana 47907/Etats-Unis (1 aut., 2 aut.); Center for Pharmaceutical Biotechnology and Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S/Ashland, Illinois 60607/Etats-Unis (3 aut., 4 aut., 5 aut., 9 aut., 10 aut.); Center for Disease Control and Prevention/Atlanta, Georgia/Etats-Unis (6 aut.); Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine/Maywood, Illinois/Etats-Unis (7 aut., 8 aut.); Department of Chemistry, University of Illinois at Chicago/Chicago, Illinois 60607/Etats-Unis
DT :	Publication en série; Correspondance, lettre; Niveau analytique
SO :	Journal of medicinal chemistry : (Print); ISSN 0022-2623; Coden JMCMAR; Etats-Unis; Da. 2005; Vol. 48; No. 22; Pp. 6767-6771; Bibl. 18 ref.
LA :	Anglais
EA :	Design, synthesis, and biological evaluation of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease (SARS-3CLpro) inhibitors for severe acute respiratory syndrome coronavirus (SARS-CoV) are described. These inhibitors exhibited antiviral activity against SARS-CoV in infected cells in the micromolar range. An X-ray crystal structure of our lead inhibitor (4) bound to SARS-3CLpro provided important drug-design templates for the design of small-molecule inhibitors.
CC :	002B02S05
FD :	Synthèse chimique; Composé peptidomimétique; Virus syndrome respiratoire aigu sévère; Inhibiteur protease; Composé non peptide; Cétoamide; Carboxamide; Lactame; Hétérocycle oxygène azote; Hétérocycle azote; In vitro; Complexe enzyme inhibiteur; Modèle moléculaire; Activité biologique; Composé vinylique; Peptidases; Inhibiteur enzyme; Antiviral; Modélisation; Pyrrolidine-3-pent-2-énoïque acide(γ-[(5-méthyl-2-[4-méthyl-3-([(5- méthylisoxazol-3-yl)carbonyl]amino)-2-oxopentyl]hex-4- énoyl)amino]-2-oxo) ester éthyle; Pyrrolidin-2-one dérivé; Isoxazole-3-carboxamide dérivé
FG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Hydrolases; Enzyme
ED :	Chemical synthesis; Peptidomimetic compound; Severe acute respiratory syndrome virus; Protease inhibitor; Non peptide compound; Ketoamide; Carboxamide; Lactam; Oxygen nitrogen heterocycle; Nitrogen heterocycle; In vitro; Inhibitor enzyme complex; Molecular model; Biological activity; Vinylic compound; Peptidases; Enzyme inhibitor; Antiviral; Modeling
EG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Hydrolases; Enzyme
SD :	Síntesis química; Compuesto peptidomimético; Severe acute respiratory syndrome virus; Inhibidor proteasa; Compuesto no péptido; Cetoamida; Carboxamida; Lactamo; Heterociclo oxígeno nitrógeno; Heterociclo nitrógeno; In vitro; Complejo enzima inhibidor; Modelo molecular; Actividad biológica; Compuesto vinílico; Peptidases; Inhibidor enzima; Antiviral; Modelización
LO :	INIST-9165.354000131970830010
ID :	06-0152064

Links to Exploration step

Pascal:06-0152064

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors</title>
<author><name sortKey="Ghosh, Arun K" sort="Ghosh, Arun K" uniqKey="Ghosh A" first="Arun K." last="Ghosh">Arun K. Ghosh</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Chemistry and Medicinal Chemistry, Purdue University</s1>
<s2>West Lafayette, Indiana 47907</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Chemistry, University of Illinois at Chicago</s1>
<s2>Chicago, Illinois 60607</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kai Xi" sort="Kai Xi" uniqKey="Kai Xi" last="Kai Xi">KAI XI</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Chemistry and Medicinal Chemistry, Purdue University</s1>
<s2>West Lafayette, Indiana 47907</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ratia, Kiira" sort="Ratia, Kiira" uniqKey="Ratia K" first="Kiira" last="Ratia">Kiira Ratia</name>
<affiliation><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology and Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1>
<s2>Ashland, Illinois 60607</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Santarsiero, Bernard D" sort="Santarsiero, Bernard D" uniqKey="Santarsiero B" first="Bernard D." last="Santarsiero">Bernard D. Santarsiero</name>
<affiliation><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology and Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1>
<s2>Ashland, Illinois 60607</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wentao Fu" sort="Wentao Fu" uniqKey="Wentao Fu" last="Wentao Fu">WENTAO FU</name>
<affiliation><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology and Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1>
<s2>Ashland, Illinois 60607</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Harcourt, Brian H" sort="Harcourt, Brian H" uniqKey="Harcourt B" first="Brian H." last="Harcourt">Brian H. Harcourt</name>
<affiliation><inist:fA14 i1="03"><s1>Center for Disease Control and Prevention</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rota, Paul A" sort="Rota, Paul A" uniqKey="Rota P" first="Paul A." last="Rota">Paul A. Rota</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine</s1>
<s2>Maywood, Illinois</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C." last="Baker">Susan C. Baker</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine</s1>
<s2>Maywood, Illinois</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Johnson, Michael E" sort="Johnson, Michael E" uniqKey="Johnson M" first="Michael E." last="Johnson">Michael E. Johnson</name>
<affiliation><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology and Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1>
<s2>Ashland, Illinois 60607</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mesecar, Andrew D" sort="Mesecar, Andrew D" uniqKey="Mesecar A" first="Andrew D." last="Mesecar">Andrew D. Mesecar</name>
<affiliation><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology and Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1>
<s2>Ashland, Illinois 60607</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0152064</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 06-0152064 INIST</idno>
<idno type="RBID">Pascal:06-0152064</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000539</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors</title>
<author><name sortKey="Ghosh, Arun K" sort="Ghosh, Arun K" uniqKey="Ghosh A" first="Arun K." last="Ghosh">Arun K. Ghosh</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Chemistry and Medicinal Chemistry, Purdue University</s1>
<s2>West Lafayette, Indiana 47907</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Chemistry, University of Illinois at Chicago</s1>
<s2>Chicago, Illinois 60607</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kai Xi" sort="Kai Xi" uniqKey="Kai Xi" last="Kai Xi">KAI XI</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Chemistry and Medicinal Chemistry, Purdue University</s1>
<s2>West Lafayette, Indiana 47907</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ratia, Kiira" sort="Ratia, Kiira" uniqKey="Ratia K" first="Kiira" last="Ratia">Kiira Ratia</name>
<affiliation><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology and Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1>
<s2>Ashland, Illinois 60607</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Santarsiero, Bernard D" sort="Santarsiero, Bernard D" uniqKey="Santarsiero B" first="Bernard D." last="Santarsiero">Bernard D. Santarsiero</name>
<affiliation><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology and Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1>
<s2>Ashland, Illinois 60607</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wentao Fu" sort="Wentao Fu" uniqKey="Wentao Fu" last="Wentao Fu">WENTAO FU</name>
<affiliation><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology and Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1>
<s2>Ashland, Illinois 60607</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Harcourt, Brian H" sort="Harcourt, Brian H" uniqKey="Harcourt B" first="Brian H." last="Harcourt">Brian H. Harcourt</name>
<affiliation><inist:fA14 i1="03"><s1>Center for Disease Control and Prevention</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rota, Paul A" sort="Rota, Paul A" uniqKey="Rota P" first="Paul A." last="Rota">Paul A. Rota</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine</s1>
<s2>Maywood, Illinois</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C." last="Baker">Susan C. Baker</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine</s1>
<s2>Maywood, Illinois</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Johnson, Michael E" sort="Johnson, Michael E" uniqKey="Johnson M" first="Michael E." last="Johnson">Michael E. Johnson</name>
<affiliation><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology and Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1>
<s2>Ashland, Illinois 60607</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mesecar, Andrew D" sort="Mesecar, Andrew D" uniqKey="Mesecar A" first="Andrew D." last="Mesecar">Andrew D. Mesecar</name>
<affiliation><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology and Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1>
<s2>Ashland, Illinois 60607</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of medicinal chemistry : (Print)</title>
<title level="j" type="abbreviated">J. med. chem. : (Print)</title>
<idno type="ISSN">0022-2623</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of medicinal chemistry : (Print)</title>
<title level="j" type="abbreviated">J. med. chem. : (Print)</title>
<idno type="ISSN">0022-2623</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Biological activity</term>
<term>Carboxamide</term>
<term>Chemical synthesis</term>
<term>Enzyme inhibitor</term>
<term>In vitro</term>
<term>Inhibitor enzyme complex</term>
<term>Ketoamide</term>
<term>Lactam</term>
<term>Modeling</term>
<term>Molecular model</term>
<term>Nitrogen heterocycle</term>
<term>Non peptide compound</term>
<term>Oxygen nitrogen heterocycle</term>
<term>Peptidases</term>
<term>Peptidomimetic compound</term>
<term>Protease inhibitor</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Vinylic compound</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Synthèse chimique</term>
<term>Composé peptidomimétique</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Inhibiteur protease</term>
<term>Composé non peptide</term>
<term>Cétoamide</term>
<term>Carboxamide</term>
<term>Lactame</term>
<term>Hétérocycle oxygène azote</term>
<term>Hétérocycle azote</term>
<term>In vitro</term>
<term>Complexe enzyme inhibiteur</term>
<term>Modèle moléculaire</term>
<term>Activité biologique</term>
<term>Composé vinylique</term>
<term>Peptidases</term>
<term>Inhibiteur enzyme</term>
<term>Antiviral</term>
<term>Modélisation</term>
<term>Pyrrolidine-3-pent-2-énoïque acide(γ-[(5-méthyl-2-[4-méthyl-3-([(5-méthylisoxazol-3-yl)carbonyl]amino)-2-oxopentyl]hex-4-énoyl)amino]-2-oxo) ester éthyle</term>
<term>Pyrrolidin-2-one dérivé</term>
<term>Isoxazole-3-carboxamide dérivé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Design, synthesis, and biological evaluation of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease (SARS-3CLpro) inhibitors for severe acute respiratory syndrome coronavirus (SARS-CoV) are described. These inhibitors exhibited antiviral activity against SARS-CoV in infected cells in the micromolar range. An X-ray crystal structure of our lead inhibitor (4) bound to SARS-3CLpro provided important drug-design templates for the design of small-molecule inhibitors.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-2623</s0>
</fA01>
<fA02 i1="01"><s0>JMCMAR</s0>
</fA02>
<fA03 i2="1"><s0>J. med. chem. : (Print)</s0>
</fA03>
<fA05><s2>48</s2>
</fA05>
<fA06><s2>22</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GHOSH (Arun K.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KAI XI</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>RATIA (Kiira)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SANTARSIERO (Bernard D.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>WENTAO FU</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>HARCOURT (Brian H.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ROTA (Paul A.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BAKER (Susan C.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>JOHNSON (Michael E.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MESECAR (Andrew D.)</s1>
</fA11>
<fA14 i1="01"><s1>Departments of Chemistry and Medicinal Chemistry, Purdue University</s1>
<s2>West Lafayette, Indiana 47907</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology and Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1>
<s2>Ashland, Illinois 60607</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Center for Disease Control and Prevention</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine</s1>
<s2>Maywood, Illinois</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Chemistry, University of Illinois at Chicago</s1>
<s2>Chicago, Illinois 60607</s2>
<s3>USA</s3>
</fA14>
<fA20><s1>6767-6771</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>9165</s2>
<s5>354000131970830010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>18 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0152064</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CR</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of medicinal chemistry : (Print)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Design, synthesis, and biological evaluation of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease (SARS-3CLpro) inhibitors for severe acute respiratory syndrome coronavirus (SARS-CoV) are described. These inhibitors exhibited antiviral activity against SARS-CoV in infected cells in the micromolar range. An X-ray crystal structure of our lead inhibitor (4) bound to SARS-3CLpro provided important drug-design templates for the design of small-molecule inhibitors.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Synthèse chimique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Chemical synthesis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Síntesis química</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Composé peptidomimétique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Peptidomimetic compound</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Compuesto peptidomimético</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Inhibiteur protease</s0>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Protease inhibitor</s0>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Inhibidor proteasa</s0>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Composé non peptide</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Non peptide compound</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Compuesto no péptido</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Cétoamide</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Ketoamide</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Cetoamida</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Carboxamide</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Carboxamide</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Carboxamida</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Lactame</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Lactam</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Lactamo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Hétérocycle oxygène azote</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Oxygen nitrogen heterocycle</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Heterociclo oxígeno nitrógeno</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Hétérocycle azote</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Nitrogen heterocycle</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Heterociclo nitrógeno</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>In vitro</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>In vitro</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>In vitro</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Complexe enzyme inhibiteur</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Inhibitor enzyme complex</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Complejo enzima inhibidor</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Modèle moléculaire</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Molecular model</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Modelo molecular</s0>
<s5>15</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Activité biologique</s0>
<s5>16</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Biological activity</s0>
<s5>16</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Actividad biológica</s0>
<s5>16</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Composé vinylique</s0>
<s5>17</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Vinylic compound</s0>
<s5>17</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Compuesto vinílico</s0>
<s5>17</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
<s5>32</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
<s5>32</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
<s5>32</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>33</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>33</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>33</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>34</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>34</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>34</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Modélisation</s0>
<s5>35</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Modeling</s0>
<s5>35</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Modelización</s0>
<s5>35</s5>
</fC03>
<fC03 i1="20" i2="X" l="FRE"><s0>Pyrrolidine-3-pent-2-énoïque acide(γ-[(5-méthyl-2-[4-méthyl-3-([(5-méthylisoxazol-3-yl)carbonyl]amino)-2-oxopentyl]hex-4-énoyl)amino]-2-oxo) ester éthyle</s0>
<s2>NK</s2>
<s2>FR</s2>
<s4>INC</s4>
<s5>76</s5>
</fC03>
<fC03 i1="21" i2="X" l="FRE"><s0>Pyrrolidin-2-one dérivé</s0>
<s2>NK</s2>
<s4>INC</s4>
<s5>77</s5>
</fC03>
<fC03 i1="22" i2="X" l="FRE"><s0>Isoxazole-3-carboxamide dérivé</s0>
<s2>NK</s2>
<s4>INC</s4>
<s5>78</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fN21><s1>093</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 06-0152064 INIST</NO>
<ET>Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors</ET>
<AU>GHOSH (Arun K.); KAI XI; RATIA (Kiira); SANTARSIERO (Bernard D.); WENTAO FU; HARCOURT (Brian H.); ROTA (Paul A.); BAKER (Susan C.); JOHNSON (Michael E.); MESECAR (Andrew D.)</AU>
<AF>Departments of Chemistry and Medicinal Chemistry, Purdue University/West Lafayette, Indiana 47907/Etats-Unis (1 aut., 2 aut.); Center for Pharmaceutical Biotechnology and Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S/Ashland, Illinois 60607/Etats-Unis (3 aut., 4 aut., 5 aut., 9 aut., 10 aut.); Center for Disease Control and Prevention/Atlanta, Georgia/Etats-Unis (6 aut.); Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine/Maywood, Illinois/Etats-Unis (7 aut., 8 aut.); Department of Chemistry, University of Illinois at Chicago/Chicago, Illinois 60607/Etats-Unis</AF>
<DT>Publication en série; Correspondance, lettre; Niveau analytique</DT>
<SO>Journal of medicinal chemistry : (Print); ISSN 0022-2623; Coden JMCMAR; Etats-Unis; Da. 2005; Vol. 48; No. 22; Pp. 6767-6771; Bibl. 18 ref.</SO>
<LA>Anglais</LA>
<EA>Design, synthesis, and biological evaluation of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease (SARS-3CLpro) inhibitors for severe acute respiratory syndrome coronavirus (SARS-CoV) are described. These inhibitors exhibited antiviral activity against SARS-CoV in infected cells in the micromolar range. An X-ray crystal structure of our lead inhibitor (4) bound to SARS-3CLpro provided important drug-design templates for the design of small-molecule inhibitors.</EA>
<CC>002B02S05</CC>
<FD>Synthèse chimique; Composé peptidomimétique; Virus syndrome respiratoire aigu sévère; Inhibiteur protease; Composé non peptide; Cétoamide; Carboxamide; Lactame; Hétérocycle oxygène azote; Hétérocycle azote; In vitro; Complexe enzyme inhibiteur; Modèle moléculaire; Activité biologique; Composé vinylique; Peptidases; Inhibiteur enzyme; Antiviral; Modélisation; Pyrrolidine-3-pent-2-énoïque acide(γ-[(5-méthyl-2-[4-méthyl-3-([(5- méthylisoxazol-3-yl)carbonyl]amino)-2-oxopentyl]hex-4- énoyl)amino]-2-oxo) ester éthyle; Pyrrolidin-2-one dérivé; Isoxazole-3-carboxamide dérivé</FD>
<FG>Coronavirus; Coronaviridae; Nidovirales; Virus; Hydrolases; Enzyme</FG>
<ED>Chemical synthesis; Peptidomimetic compound; Severe acute respiratory syndrome virus; Protease inhibitor; Non peptide compound; Ketoamide; Carboxamide; Lactam; Oxygen nitrogen heterocycle; Nitrogen heterocycle; In vitro; Inhibitor enzyme complex; Molecular model; Biological activity; Vinylic compound; Peptidases; Enzyme inhibitor; Antiviral; Modeling</ED>
<EG>Coronavirus; Coronaviridae; Nidovirales; Virus; Hydrolases; Enzyme</EG>
<SD>Síntesis química; Compuesto peptidomimético; Severe acute respiratory syndrome virus; Inhibidor proteasa; Compuesto no péptido; Cetoamida; Carboxamida; Lactamo; Heterociclo oxígeno nitrógeno; Heterociclo nitrógeno; In vitro; Complejo enzima inhibidor; Modelo molecular; Actividad biológica; Compuesto vinílico; Peptidases; Inhibidor enzima; Antiviral; Modelización</SD>
<LO>INIST-9165.354000131970830010</LO>
<ID>06-0152064</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000539 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000539 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0152064
   |texte=   Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors

Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri